Nurix Therapeutics Reports Q2 Financials with Wider Loss, Revenue Drop, and Major Roche Deal
Nurix Therapeutics announced its second-quarter financial results, revealing an expanded net loss and a decrease in revenue. The company also emphasized a substantial $700 million partnership agreement with Roche. These figures provide an update on the biotech firm's recent performance and strategic collaborations.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.